IASLC Conflict of Interest
The integrity and reputation of IASLC and its programs relies on the avoidance of real or perceived conflicts of interest.
IASLC is determined to provide scientific independence, objectivity, and rigor to its educational activities through processes including appropriate disclosure of real, potential or perceived conflicts of interests.
The following policy has been designed to harmonize with the standards of other international organizations dedicated to progress in cancer care and research. This policy document enables a framework for the IASLC and its Ethics Committee to manage any disclosures of interests that might be construed as resulting in real, potential or perceived conflicts.
The IASLC conflict of interest policy should not be regarded as creating a presumption of impropriety in the existence of financial interests or other relationships of a commercial nature. IASLC conflict of interest policy will rely on individual’s disclosing interests.
View the Complete IASLC Conflict of Interest Policy (Revised April 2016)
View the IASLC Conflict of Interest Explanatory Notes (Frequently Asked Questions)
View the Conflict of Interest Disclosure Form - NOTE: Committee and Board members have been emailed a link for completion of the form online. If you have not received via email, please contact firstname.lastname@example.org.
Below are links to the application for the IASLC 20th World Conference on Lung Cancer, Barcelona, Spain. The conference will take place in November 2019. Applications must be submitted by October 1, 2016.
Download Application (Word)
Download Application (PDF)
Role of the Regional Organizing Committee (ROC) for 20th WCLC in Barcelona. Spain, 2019
The ROC will consist of 15-20 IASLC members located in Europe. The ROC provides regional leadership to guide scientific program, social events and logistics for the WCLC. The ROC contributes members toward the 50% of Core Program Committee from Europe region (25% each from other regions, Asia/ROW; North America). The ROC establishes the Program Committee and makes recommendations regarding speakers, innovative ideas, schedules, facilities, pricing and formats. The ROC works with International Conference Services (ICS) as a professional Conference organizer (PCO) that is contracted by the IASLC to support the 20th WCLC in Barcelona to plan the Opening Ceremony, the President’s/Faculty Dinner and the Closing Gala Ceremony including venue and entertainment. The ROC plans onsite workshops. The ROC assists with Press releases and marketing efforts. The ROC encourages local and regional sponsorships and regional attendance and activities to support strategic plans for the region. The ROC provides regional volunteers to support planning and onsite activities. The ROC provides programs for trainees, advocates, allied health professionals and may plan “hands on” workshops and other activities. The ROC ensures that the conference complies with all CME and local laws and regulations. The ROC works with ICS, the IASLC Office, the IASLC Board and Staff in oversight of the Conference budget.
The Chair of the ROC serves as the Conference President and serves on the IASLC Board (without vote) for the 1 years prior to the WCLC. The ROC may have a co-Chair or a conference co-President but the co-President does not serve on the IASLC Board.
CAP / IASLC / AMP Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline, “Molecular Testing Guideline for the Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors,” which establishes standards for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine, the Journal of Thoracic Oncology, and the Journal of Molecular Diagnostics.
The IASLC offers the following resources:
View the full article on the JTO Website
Download a Summary of the Recommendations
View the Patient Guide
View the slide deck of the webcast
View the Videos about the guideline
IASLC 2015 Statement on Tobacco Control and Smoking Cessation
Cigarette smoking is responsible for over 80% of all lung cancer cases, while exposure to air pollution, radon, occupational exposures to chemicals, and having a family history of lung cancer likely accounts for the majority of remaining cases. Worldwide, lung cancer is the leading cause of cancer death. While the epidemic of cigarette induced lung cancers is now beginning to subside (particularly in men) in many high income countries as cigarette consumption has fallen, worldwide lung cancer deaths are projected to increase in the coming decades as smoking rates increase in low and middle income countries. The projected global epidemic of cigarette caused lung cancers is entirely preventable. However, controlling cigarette sales worldwide is an enormous challenge because of the economic incentives that continue to favor cigarette manufacturing. The 2010 Surgeon General’s Report on Smoking and Health noted that the reason why smokers repeatedly expose themselves to the harmful toxins in cigarette smoke, ultimately resulting in lung cancer and many types of cancers and other diseases, is nicotine addiction.
The International Association for the Study of Lung Cancer (IASLC) recognizes that the solution to the tobacco problem lies in primary prevention of tobacco initiation and in tobacco cessation by individuals addicted to nicotine. Solid research over the past several decades has demonstrated many policies, when effectively implemented, decrease the number of people using tobacco. These policies are embedded within the World Health Organization’s Framework Convention on Tobacco Control (FCTC) - a treaty that 180 countries have signed to date.
The IASLC strongly urges its members and others around the world to:
- support implementation of the FCTC in their country;
- support legal reforms in their country that hold tobacco manufacturers civilly and criminally accountable for their actions;
- support policies that prevent smoking initiation in children and youth such as raising and enforcing the legal age for purchase of tobacco to 21 years, restricting marketing, and increasing tobacco product taxes to reduce affordability;
- implement tobacco cessation programs in their clinics, hospitals and cancer centers to assist their patients achieve the best possible outcomes from their cancer treatment; and
- support policies that address alternative nicotine delivery devices, such as aerosolized nicotine products that are evidence-based and promote overall population health.
The IASLC strongly supports keeping tobacco out of trade agreements and other efforts of tobacco manufacturers to circumvent the freedom of countries to enact tobacco control policies that advance public health goals.
IASLC 2011 Statement on CT Screening for Lung Cancer
The IASLC Task Force on CT Screening reviewed the results from the National Lung Screening Trial, concluding that it is appropriate for heavy smokers ages 55 to 74 to discuss relevant lung cancer screening information with their physicians to assist them in deciding whether to undergo spiral CT screening.
View the complete statement in English
View the complete statement in Spanish
View the complete statement in Italian
View the complete statement in Japanese
View the complete statement in Korean
View the complete statement in French
View the complete statement in Danish
Market Research Policies
Market research companies must complete and submit to IASLC the "Market Research Submission" form. The request must include the name of the firm for which the company is conducting research and the subject and reason for the research. The requesting firm must certify to IASLC that the research will be conducted in accordance with all applicable legal requirements. The requesting firm must also indicate whether any remuneration, including coupons or token giveaways, will be provided to participants and whether any identifiable information (e.g. names, addresses, e-mail addresses) will be collected from participants. If approved by IASLC, they may conduct the approved survey, questionnaire, or other market research activities in the Exhibit Hall. Market Research activities and solicitations must be contained within the booth. Exhibit personnel may not solicit attendees outside of their booth. Failure to comply will lead to expulsion from the Exhibit Hall. Giveaways must be made available upon request to all registered attendees, whether or not they participated in the research activity. IASLC reserves the right to decline permission for any market research activity at the meeting.
IASLC Organizational Structure
IASLC is organized as a nonprofit corporation in the State of Colorado and is recognized as a 501(c)(3) educational charity in the United States and regulated by the United States Internal Revenue Service. The membership of IASLC selects the Board of Directors and is governed by its Bylaws. The link below accesses the Bylaws approved by the members in July, 2013 which become effective at the WCLC in Sydney in October, 2013. View the IASLC Bylaws.
IASLC Membership Terms & Conditions
Describes the Terms & Conditions of membeship and online member registration. View the IASLC Membership Terms & Conditions
To provide all IASLC members and conference participants with quality service, IASLC must collect, process, and use its members’ personal information. At the same time, we want to protect the personal information you provide to us. To underscore IASLC’s commitment to protecting your privacy and the value we place on your relationship with us, IASLC has adopted the following privacy principles applicable to our handling of your personal information: View the Complete Policy & Procedures